Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Gemcitabine, and Oxaliplatin for Pancreatic Cancer
NCT00448838Phase 2Completed
- Sponsor
- University of Miami
- Start
- May 2006
- Primary completion
- Aug 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in pancreatic cancer (PC), sponsored by University of Miami. Primary endpoint: Progression-Free Survival at 6 months. Started May 2006; status: completed.
02
Drugs
KL-140
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00448838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00448838.